Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1651 1657 1678
This examiner grants 42% of resolved cases
Trent R Clarke works in Tech Center 1600 and Art Unit 1651. He has 436 resolved cases and an allowance rate of 42.0 percent. This rate indicates the frequency of successful outcomes in this environment. The median days to allowance is 1382, suggesting the prosecution period for applications in this unit.
The interview lift is 24.0 percent. This figure shows that the 42.0 percent allowance rate can be improved through direct communication. In Tech Center 1600, where the 1382 days median to allowance is the observed timeline, the 24.0 percent lift offers a path to different outcomes.
The 436 resolved cases provide a foundation for these metrics. The 42.0 percent allowance rate and the 1382 days median to allowance highlight the conditions in Art Unit 1651. The 24.0 percent interview lift suggests that practitioners have a mechanism to influence the final result. The combination of these metrics defines the current prosecution landscape for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18190660 | Using Water Ponds for Capturing Dioxide and Growing Algae | Non-Final OA | Saudi Arabian Oil Company |
| 18657413 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION | Non-Final OA | The Regents of the University of Michigan |
| 18003570 | CONTROLLING OPERATION OF A BIOREACTOR VESSEL | Non-Final OA | IPSEN BIOPHARM LIMITED |
| 18889325 | Methods and Compositions for Preserving Tissues and Organs | Non-Final OA | The General Hospital Corporation |
| 17205910 | COMPOSITIONS CONTAINING UMBILICAL CORD LINING STEM CELLS CONDITIONED MEDIUM | Final Rejection | RESTEM LLC |
| 18015207 | COMPOSITION FOR PREDICTING OR DIAGNOSING EARLY-STAGE DIFFUSE GASTRIC CANCER, COMPRISING PREPARATION FOR MEASURING LEVEL OF PEPSINOGEN II | Final Rejection | Seoul National University Hospital |
| 18614071 | Fetal Microchimeric Cells and EVs for Regenerative Medicine in Women's Health | Non-Final OA | University of Vermont and State Agricultural College |
| 18684262 | METHODS COMPRISING THERAPEUTIC COMPOUNDS AND IN VITRO MAMMALIAN SKIN | Non-Final OA | AMGEN INC. |
| 17923679 | FUNCTIONALIZED POLY(GLYCEROL SEBACATE)S AND USES THEREOF | Final Rejection | CORNELL UNIVERSITY |
| 17494690 | MODULATING ISCHEMIC INJURY | Final Rejection | Noveome Biotherapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy